

## Phenotypic and genotypic variations in *Candida albicans* isolates from Romanian patients

Irina Rosca<sup>1</sup>, Andra-Cristina Bostanaru<sup>2</sup>, Bogdan Minea<sup>3</sup>, Valentin Nastasa<sup>2</sup>, Julian Gherghel<sup>4</sup>, Carmen-Valentina Panzaru<sup>3</sup>, Mihai Mares<sup>2\*</sup>, Valentina Ruxandra Moroti-Constantinescu<sup>5,6</sup>

1. Centre of Advanced Research in Bionanoconjugates and Biopolymers, Petru Poni Institute of Macromolecular Chemistry, Iasi-Romania

2. Laboratory of Antimicrobial Chemotherapy, Ion Ionescu de la Brad University, Iasi-Romania

3. Gr. T. Popa University of Medicine and Pharmacy, Iasi-Romania

4. Department of Biology, Case Western Reserve University, Cleveland-USA

5. Matei Bals National Institute of Infectious Diseases, Bucharest-Romania

6. Carol Davila University of Medicine and Pharmacy, Bucharest-Romania

### Abstract

**Background:** During the last two decades a major increase in the proportion of severe fungal infections has been noted due to the excessive use of broad-spectrum antibiotics, catheters, and a growing number of immunocompromised patients.

**Objectives:** This is the first investigation providing complete data regarding the phenotypic and genotypic profiles of *Candida albicans* (*C. albicans*) isolates in Romanian patients.

**Methods:** We investigated 301 isolates in terms of genotype determination (G), resistogram (R), phospholipase activity (Pl), haemolysis (Hl), proteinase activity (Pt), and biofilm formation (BF).

**Results:** The analyzed isolates of *C. albicans* showed low values for Pt (61.73%), Hl (95.49%), and BF (60.71%), and did not present any Pl activity (92.23%). More than half of the investigated samples were genotype A with 450 bp (52.92%) and the majority (86.19%) were resistant to sodium selenite (A), boric acid (B), sodium periodate (D) and silver nitrate (E), but sensitive to cetrizide (-). One-way ANOVA analysis revealed significant effects of the infection site on biofilm formation ( $p = 0.0137$ ) and no significant correlation was found between the genotype (A, B, C) and the infection site ( $p = 0.449$ ).

**Conclusions:** Based on the obtained results it can be concluded that *C. albicans* isolates in Romanian patients exhibit different genotypic and phenotypic patterns, and no significant correlations between genotype and infection site could be observed.

**Keywords:** *Candida albicans*, infection site, genotype, phenotypes, Romania

Received: 7<sup>th</sup> May 2018; Accepted: 21<sup>st</sup> June 2018; Published: 6<sup>th</sup> July 2018

\*Corresponding author: Mihai Mares, Ion Ionescu de la Brad University, Iasi, Romania.  
E-mail: mihaimares@fungi.ro

## Introduction

The fourth source of bloodstream infections as prevalence, *Candida* yeasts remain the most recurrent fungal pathogen in humans [1]. *C. albicans* is the most frequent species causing mortality rates of 50% [2-3]. *C. albicans* is a member of the normal human microbiome, usually being commensal and harmless, but under certain circumstances, it becomes an opportunistic pathogen and produces candidiasis if the defence mechanisms of the host are damaged [4].

*Candida* infections are a major health issue supplied, paradoxically, by the improvements in medical care, where the most important predisposing factors for the infections are the use of antibiotics, indwelling catheters, immunosuppression, chemotherapy and radiotherapy [5-7]. *C. albicans* produces two major types of infections: superficial infections, such as oral or vaginal candidiasis, and deep-seated life-threatening systemic infections (such as *Candida* endocarditis and acute invasive candidiasis as causes of sepsis) [8].

Several factors that contribute to the pathogenic potential of this fungus have been identified such as biofilm formation, the secretion of hydrolases, contact sensing and thigmotropism and phenotypic switching [9]. Understanding how these mechanisms and factors contribute to infection has significantly increased during the last years, but at the same time, new virulence strategies have recently been observed.

Antifungal therapy is a critical component of the patient management for acute and chronic diseases [10]. The presence of oral *Candida* yeasts is considered a signal indicative of immune system impairment and can be correlated with a progressive disease [11].

Oral candidiasis is one of the most frequent types of *Candida* infection found especially in denture wearers and individuals with severe conditions (e.g. HIV-infected patients), patients under antibiotic or chemotherapy, and patients

with systemic diseases such as diabetes [12]. HIV-infected patients are possible to mycoses as cell-mediated immunity decays [12].

In diabetic patients, hyperglycaemia can favour several infectious diseases ranging from superficial candidiasis to deep-seated mycoses [13]. Because of the poor immune system, oral candidiasis development is often faster and more severe [10]. Candidemia incidence is statistically correlated with hyperglycaemia and is a serious mortality cause in patients with diabetes [14].

*Candida* has the ability to produce various virulence factors that amplify their property to colonize mucosal or synthetic surfaces and, afterwards, to invade the host tissues. Studies regarding isolates from people with candidemia are more numerous and to our knowledge, the present study is the first investigation providing complete data regarding the phenotypic and genotypic profiles of *C. albicans* strains isolated in Romanian patients.

We report a screening of 301 clinical yeast isolates in terms of phenotypic and genotypic profiles: genotype determination (G), resistogram (R), phospholipase activity (Pl), haemolysis (Hl), proteinase activity (Pt) and biofilm formation (BF) in order to investigate the relationship between *C. albicans* strains and their pathogenicity.

## Material and methods

### *Clinical isolate processing*

Three-hundred and one *C. albicans* clinical isolates were collected in four tertiary hospitals from different regions of Romania (i.e. Iași, Cluj-Napoca, Timișoara, and Tîrgu Mureș). Samples were recovered from bloodstream infections (BSI), deep-seated mycoses (DEEP) (lower respiratory tract, peritoneal cavity, upper urinary tract in non-catheterized patients, and cerebrospinal fluid) and superficial mycoses (SUP) (female genital tract, oropharyngeal, and

gastro-intestinal tract). The isolates were collected from patients who presented at the same time at least two of the following risk factors: low birth weight (<1500 g), old age (>65 years), insulin-dependent diabetes mellitus, recent major surgery, broad-spectrum antibiotic therapy, central venous catheter, organ transplantation, immunosuppression (HIV infection or other predisposing conditions), total parenteral nutrition or mechanical ventilation.

The isolates were presumptively identified by local hospital laboratories and then submitted to the Laboratory of Antimicrobial Chemotherapy from the Department of Public Health of "Ion Ionescu de la Brad" University, Iași, Romania. The last identification was performed using ID32C strips (bioMérieux, France). Isolates identified as *C. albicans* were also tested using duplex PCR by a method previously described by Romeo & Criseo [15].

#### ***C. albicans* genotype determination (G) by Polymerase Chain Reaction (PCR)**

In order to extract DNA, two colonies of *C. albicans* were taken from Sabouraud Dextrose Agar (SDA) plates and suspended in 200 µl sterile distilled water in a sterile Eppendorf tube. DNA was obtained by lysing the cells at 95°C for 5 min and by immersing in ice. PCR was performed according to the method previously described [16-17] using the primers CA-NT-L (5'-ATAAGGGAAGTCGGCAAAATAGATC-CGTAA-3') and CA-NT-R (5'-CCTTGGCT-GTGGTTTCGCTAGATAGTAGAT-3'). The products were analysed by electrophoresis on 1.5% agarose gels in Tris-borate-EDTA (TBE) buffer at 70 V for 30 min and were subsequently stained in a solution of 0.5 µg of ethidium bromide per mL.

According to the PCR products, the genotypes of *C. albicans* can be classified by the size of DNA amplified into 3 groups: 450 bp for group A, 840 bp for group B, 450 and 840 bp for group C) [17-19].

Resistogram (R). The resistogram typing of the isolates of *C. albicans* was performed according to McCreight and Warnock method [20], with a few modifications [21]. The plates containing chemicals at different concentrations (mg/mL Sabouraud dextrose agar) used for the resistogram typing were: sodium selenite: 0.1, 0.2, 0.3, 0.4 (A); boric acid: 1.15, 1.3, 1.45, 1.6 (B); cetrimide: 0.06, 0.08, 0.1, 0.12 (C); sodium periodate: 0.01, 0.02, 0.03, 0.04 (D); silver nitrate, 0.0075, 0.01, 0.0125, 0.015 (E) [20]. After incubation for 40 h at 37°C, the growth of each strain was read. For example, the resistogram "AB - - E" signifies that the tested strain was resistant to sodium selenite (A), boric acid (B) and silver nitrate (E), but sensitive to cetrimide (-) and sodium periodate (-) [21].

Phospholipase activity assays (Pl). Extracellular phospholipase activity was evaluated according to the method described by Prince *et al.* [22] and Sanita *et al.* [8]. After incubation the diameter of hyaline zones around the colonies and the diameter of the colonies was measured using Image J software [23]. The phospholipase activity (Pl value) was measured in terms of the ratio of the diameter of the colony to the total diameter of colony plus the precipitation zone. Pl were also evaluated as follows: Pl < 0.64 (high), 0.64 ≤ Pl < 1 (low) and Pl = 1 (none).

Haemolysis (Hl) was evaluated using a blood plate assay [24-25]. After incubation, the plates were measured using Image J software [23]. The presence of a translucent zone of haemolysis around the inoculum site, viewed with transmitted light, indicated positive haemolytic activity. Haemolysin activity (Hl value) was measured and categorised as follows: Hl < 0.64 (high), 0.64 ≤ Hl < 1 (low) and Hl = 1 (none).

Proteinase activity (Pt) determination was made by the agar plate method as previously described by Barros *et al.* [26]. The plates were incubated at 37°C for 72 h and the enzymatic activity was determined by the formation of a

halo around the colony, measured in terms of the ratio of the diameter of the colony to the total diameter of colony plus zone of precipitation. The proteinase activity (Pt value) was measured with the aid of Image J software and categorised as follows: Pt< 0.64 (high), 0.64 ≤ Pt < 1 (low) and Pt = 1 (none) [23].

**Biofilm formation (BF).** The assessment of the biofilm forming capacity of the yeasts was performed following protocols published by Pierce *et al.* [27] with some modifications. The method is based on inducing the formation of biofilms in 96-well microplates and on the metabolic capability of live yeast cells to reduce a tetrazolium salt (XTT) to water soluble coloured formazan compounds [28]. The colour intensity of the formazan solution was measured with a microplate reader.

The *C. albicans* SC5314 strain, which forms abundant biofilms with a complex structure, was used both for quality control and as a unit of measure for comparison. Isolates were classified as low biofilm formers (LBF) or high biofilm formers (HBF) if their biomass absorbance was less than the first quartile ( $Q_1$  OD<sub>570</sub> = 0.366) or greater than the third quartile ( $Q_3$  OD<sub>570</sub> = 1.286), respectively. The isolates in between the first and third quartile ( $Q_1-Q_3$ ) were defined as intermediate biofilm formers (IBF).

Descriptive statistics, chi-square test, one-way ANOVA, and Pearson's correlation coefficient were used to analyze the obtained data.

## Results

In terms of *C. albicans* infection site, of the 301 samples, 57.47% were from superficial infections (SUP, n=173) like: vaginal discharge (n=39), vaginal discharge in pregnant women (n=29), pharyngeal exudate (n=4), onycomycosis (n=2), gastrointestinal tract (n=2), scraped lingual (n=5), oral sampling (n=32), oral sampling from patients with diabetes (n=6), oral sampling

from pregnant women (n=4), oral sampling from HIV patients (n=26), oral sampling from denture patients (n=3), oral sampling from TBC patients (n=1), nail sample (n=1), balanitis sample (n=1), faeces samples (n=11), faeces samples from HIV patients (n=6), and colecistitis sample (n=1). *C. albicans* was sampled 20.59% from blood culture (BSI, n=62) and 21.92% of strains were from deep-seated life-threatening systemic infections (DEEP, n=66) like: urine (n=3), urine from HIV patients (n=1), respiratory tract (n=3), cerebrospinal fluid (n=1), bronchial aspirate (n=2), bronchial aspirate from TBC patients (n=15), sputum (n=26), sputum from TBC patients (n=8) and drain tube (n=7) (Table 1).

**Genotype determination (G).** *C. albicans* were classified into three different groups, based on the length of polymerase chain reaction (PCR) amplification product, namely genotypes A with 52.92%, B with 17.85%, respectively C, with 29.20% (Table 1).

**Resistogram (R).** The 301 strains were grouped into 5 resistotypes (Table 1). The majority were resistant to sodium selenite (A), boric acid (B), sodium periodate (D) and silver nitrate (E), but sensitive to cetrimide (-) (86.19%).

**Phospholipase activity (Pl).** *C. albicans* isolates presented low phospholipase activity (Pl) with values between 0.61 and 1 (Figure 1). The low activity of phospholipases was observed in 7.76% of the isolates (Table 1).

**Haemolysis (HI).** The haemolytic activity of different *C. albicans* strains obtained from a variety of clinical sources (Figure 1) was evaluated. Most of the investigated strains presented low haemolytic activity (95.49%) (Table 1).

**Proteinases (Pt).** Most of the analyzed strains presented a low level of proteinases (61.73%), and the rest of the strains did not present any Pt (38.27%) (Table 1, Figure 1).

**Biofilm formation (BF).** Biofilm formation is heterogeneous, with isolates classified as either high or low biofilm formers (LBF and HBF)

**Table 1. Statistical analysis of the *C. albicans* phenotypic and genotypic profile**

Infection site	
SUP	57.475 %
BSI	20.598 %
DEEP	21.922 %
Genotype	
A	52.922 %
B	17.857 %
C	29.220 %
Resistogram	
AB-DE	86.816 %
AB- -E	0.643 %
ABCDE	1.929 %
-B-DE	5.466 %
A- -DE	5.144 %
Phospholipases activity	
Pi-low	7.766 %
Pi-none	92.233 %
Hemolysis	
Hl-low	95.498 %
Hl-none	4.501 %
Proteinases	
Pt-low	61.736 %
Pt-none	38.263 %
Biofilm formation	
LBF	60.771 %
IBF	37.299 %
HBF	1.929 %

**Infection site:** SUP-superficial infections, BSC-blood stream infections, DEEP-deep-seated life-threatening systemic infections;

**Genotype:** A: 450 bp, B: 840 bp, C: 450&840 bp;


**Resistogram:** AB-DE: resistant to sodium selenite (A), boric acid (B), sodium periodate (D), silver nitrate (E) and sensitive to cetrimide(C); AB- -E: resistant to sodium selenite (A), boric acid (B), silver nitrate (E) and sensitive to cetrimide (C) and sodium periodate (D); ABCDE: resistant to sodium selenite (A), boric acid (B), cetrimide (C), sodium periodate (D) and silver nitrate (E); -B-DE: resistant to boric acid (B), sodium periodate (D), silver nitrate (E), and sensitive to sodium selenite (A), cetrimide (C); A- -DE: resistant to sodium selenite (A), sodium periodate (D), silver nitrate (E) and sensitive to boric acid (B), cetrimide (C).

**Phospholipases:** Pi-low: low phospholipase activity, Pi-none: none phospholipase activity.

**Haemolytic activity:** Hl-low: low haemolytic activity, Hl-none: none haemolytic activity.

**Proteinases:** Pt-low: low proteinase activity, Pt-none: none proteinase activity.

**Biofilm formation:** LBF: low biofilm formers, IBF: intermediate biofilm formers, HBF: high biofilm formers.

**Fig. 1. The descriptive statistics of *C. albicans* phenotypic properties**

(Figure 1). Isolates were categorised as low biofilm formers (LBF) for 60.77% of the strains or high biofilm formers (HBF) for 1.92% if their biomass absorbance was less than the first quartile ( $Q_1$  OD570 = 0.366) or greater than the third quartile ( $Q_3$  OD570 = 1.286), respectively. Those isolates in between the first and third quartile ( $Q_1$ - $Q_3$ ) were defined as intermediate biofilm formers (37.29%) (Table 1).

Statistical analysis. One-way ANOVA revealed significant effects of prevalence on biofilm formation ( $p = 0.0137$ ) (Table 2). No other statistical significant effects were found between the analyzed parameters. The results of the chi-square test (Table 2) showed a significant positive association only between prevalence and resistograms ( $p = 0.0832$ ).

There was a strong correlation between phospholipases and haemolytic activity ( $r = 0.563$ ) and proteinases ( $r = 0.548$ ) and also between haemolytic activity and proteinases ( $r = 0.886$ ) (Table 3). No significant correlation was found between the genotype (A, B, C) and the infection site ( $p = 0.449$ ).

## Discussions

Genotype determination (G). *C. albicans* strains converge to be genetically similar, when derived from similar population groups, in correlation with the immune condition, anatomic site or geographical location [28]. It was not

**Table 2. Statistical analysis: one-way Anova and chi-square association.**

		Proteases	Phospholipases	Haemolysis	Biofilm formation	Resistogram
<b>One-way Anova</b>	Infection site	0.543	0.382	0.313	0.013*	0.432
	Genotype	0.891	0.415	0.116	0.381	0.852
<b>Chi-square</b>	Infection site	0.527	0.265	0.853	0.144	0.083*
	Genotype	0.807	0.109	0.088	0.471	0.252

The mean difference is significant ( $p \leq 0.05$ )

**Table 3. Pearson correlation between different phenotypic properties of *C. albicans* isolates**

	Proteinases	Phospholipases	Haemolytic activity	Biofilm formation
<b>Proteinases</b>	-	0.548	0.886*	0.001
<b>Phospholipases</b>	0.548*	-	0.563*	0.392
<b>Haemolytic activity</b>	0.886*	0.563*	-	0.076
<b>Biofilm formation</b>	0.001	0.392	0.076	-

\* Statistically significant positive relationship.

proved that the virulence of *C. albicans* is related to genotypes. One study found that genotype A was more prevalent among invasive isolates and that genotype B and C were more common among non-invasive isolates ( $p < 0.05$ ) [29]. Also, Al-Karaawi *et al.* [28] reported that genotype A is the most predominant type in patients with oral *Candida* infections. Interestingly, the obtained results in the current study showed no significant correlation between the genotype (A, B, C) and the infection site ( $p = 0.449$ , table 1). Moreover, our previous study showed a significant correlation between genotype and isolates from HIV patients ( $p < 0.0001$ ) (unpublished data) concluding that maybe *C. albicans* pathogenicity relies on a series of particular inherent and environmental factors mostly related to the host. Thus, for example, in order to facilitate the hyphae invasion, *Candida* has the ability to produce a variety of hydrolytic enzymes, such as proteases, lipases, phospholipases, esterase and phosphatases [25].

Resistogram (R). A direct comparison between data from the current study and the previously reported ones [20-21] in terms of resistogram methods is difficult due to the chemical con-

centrations of the used compounds, the number of strains and their prevalence. To facilitate data analysis, data from the 301 tested strains were grouped into only 5 resistotypes. The obtained general results revealed that most of the strains (86.816%) were completely resistant to sodium selenite, boric acid, sodium periodate and silver nitrate, but showed an unexpected sensitivity to cetyltrimidazole (resistogram pattern AB\_DE).

Phospholipase activity (PL), and secreted aspartyl proteinases (SPA) are determinant of not only commensal colonization, but also for the pathogenic potential of these yeasts [30]. For example, some authors showed that enzymatic secretion vary for *C. albicans* isolates of different strain and origin [31]. *C. albicans* secretes phospholipases A, B and C, which are considered to be virulence factors, being associated with the damage, adherence and penetration of the host cells [32].

Literature reports showed that 30-100% of the oral isolates produced phospholipases, with variable degree of enzymatic activity, due to the origin of the isolates, the phenotypic variability or the variation in the method employed. [23]. Vidotto *et al.* [33] did not find a relationship be-

tween phospholipase activity and genotype, regardless of the body site where the strains were collected. Their results are confirmed by this study.

Proteinase activity (Pt). *C. albicans* has various secreted hydrolytic enzymes of which secreted aspartyl proteinases contribute to the pathogenesis of candidiasis. Their role in pathogenicity is that the enzymes have the ability to degrade a number of important host factors [34]. However, some of the analyzed *C. albicans* strains proved to have a low level of proteinases and the rest of the strains did not present any proteinase activity.

Haemolysis (Hl) is known to facilitate iron acquisition from host erythrocytes, being an important virulence factor that contributes to *Candida* spp. dissemination [24]. Watanabe *et al.* [35] stipulated that the beta haemolysin in *C. albicans* is a cell wall mannoprotein. Luo *et al.* [25] noticed that 6 of 14 *Candida* species tested did not produce beta-haemolysis although mannoprotein is a universal component of the *Candida* cell wall, maybe due to the variation of the cell wall mannoprotein content in different *Candida* species. It seems that the absence of glucose in the medium altered the sugar moiety of the mannoprotein leading to the loss of beta-haemolytic activities [24]. Even if the previous studies prove that haemolysis plays an important role in *C. albicans* disseminations, most of the investigated strains presented low haemolytic activity (95.49%).

Biofilm formation (BF). The ability of the fungal cells to form biofilms is the main factor that blocks the antifungal activity [36]. Candi-daemia is often associated with the ability of *Candida* to form biofilms on indwelling medical devices such as central venous catheters and prosthesis [37]. A biofilm is a structural microbial community attached to a surface and packed with a self-produced extra-cellular matrix [38]. Biofilms are defined by resistance to antibiotics

and higher drug concentrations are required [39-40]. Biofilm formations vary between *Candida* isolates and categorizing them may help to predict how these will behave clinically [28].

There is a fundamental gap in understanding exactly what drives biofilm formation and its clinical implications. We aimed to evaluate and categorize *C. albicans* biofilms into distinct levels of biofilm formation. Our isolates were categorised mostly as low biofilm formers (LBF) for 60.77%, proving that their pathogenicity relies not only on their properties to form biofilms, but maybe on a mixture of factors related to their phenotype and definitely related to the host characteristics.

In conclusion, all the isolated and analyzed strains of *C. albicans* had strain-dependent variable levels of enzymatic activity, and they were not all biofilm producers. There were only a few significant statistical correlations in the studied virulence factors, including genotype and prevalence. Although much progress has been made in understanding the phenotypic and genotypic profile of *C. albicans*, still little is known regarding their interaction with the host.

## Acknowledgments

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 667387 WIDESPREAD 2-2014 SupraChem Lab. This work was also supported by a grant of the Romanian National Authority for Scientific Research, contract no. 26BM/16.09.2016.

## Conflict of interest

The authors declare no conflict of interest.

## References

- Wong SSW, Samaranayake LP, Seneviratne CJ. In pursuit of the ideal antifungal agent for Candida infec-

- tions: high-throughput screening of small molecules. *Drug Discov Today.* 2014 Nov;19(11):1721-0. DOI: 10.1016/j.drudis.2014.06.009
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. *Clin Microbiol Rev.* 2007 Jan;20(1):133-3. DOI: 10.1128/CMR.00029-06
  3. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. *Crit Rev Microbiol.* 2010;36(1):1-53. DOI: 10.3109/10408410903241444
  4. Kabir MA, Hussain MA, Ahmad Z. *Candida albicans*: a model organism for studying fungal pathogens. *ISRN Microbiol.* 2012 Sep 29;2012:538694.
  5. Dixon DM, McNeil MM, Cohen ML, Gellin BG, La Montagne JR. Fungal infections: a growing threat. *Public Health Rep.* 1996 May-Jun;111(3):226-5.
  6. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. *Curr Opin Infect Dis.* 2002 Dec;15(6):569-4. DOI: 10.1097/00001432-200212000-00003
  7. Ruhnke M, Maschmeyer G. Management of mycoses in patients with hematologic disease and cancer—review of the literature. *Eur J Med Res.* 2002 May 31;7(5):227-5.
  8. Sanita PV, de Oliveira Mima EG, Pavarina AC, Jorge JH, Machado AL, Vergani CE. Susceptibility profile of a Brazilian yeast stock collection of *Candida* species isolated from subjects with *Candida*-associated denture stomatitis with or without diabetes. *Oral Surg Oral Surg Oral Med Oral Pathol Oral Radiol.* 2013 Nov;116(5):562-9. DOI: 10.1016/j.oooo.2013.07.002
  9. Gow NAR, van de Veerdonk FL, Brown AJP, Neete MG. *Candida albicans* morphogenesis and host defence: discriminating invasion from colonization. *Nat Rev Microbiol.* 2011 Dec 12;10(2):112-2. DOI: 10.1038/nrmicro2711
  10. Perlin DS. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. *Drugs.* 2014 Sep;74(14):1573-5. DOI: 10.1007/s40265-014-0286-5
  11. Vargas KG, Joly S. Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals. *J Clin Microbiol.* 2002 Feb;40(2):341-0. DOI: 10.1128/JCM.40.2.341-350.2002
  12. Vergani CE, Sanitá PV, Mima EGO, Pavarina AC, Machado AL. Oral candidiasis: Conventional and alternative treatment options. In: Contreras F and Fuentes P (eds) *Candidiasis: Epidemiology, Symptoms and Treatment Options*, 1st edn. Nova Medical, New York, pp 85-115.
  13. Molero G, Díez-Orejas R, Navarro-García F, Monteoliva L, Pla J, Gil C, et al. *Candida albicans*: genetics, dimorphism and pathogenicity. *Int Microbiol.* 1998 Jun;1(2):95-106.
  14. Poradzka A, Jasik M, Karnafel W, Fiedor P. Clinical aspects of fungal infections in diabetes. *Acta Pol Pharm.* 2013 Jul-Aug;70(4):587-6.
  15. Romeo O, Criseo G. *Candida africana* and its closest relatives. *Mycoses* 2011 Nov;54(6):475-6. DOI: 10.1111/j.1439-0507.2010.01939.x
  16. McCullough MJ, Clemons KV, Stevens DA. Molecular and phenotypic characterization of genotypic *Candida albicans* subgroups and comparison with *Candida dubliniensis* and *Candida stellatoidea*. *J Clin Microbiol.* 1999 Feb;37(2):417-1.
  17. Li W, Yu D, Gao S, Lin J, Chen Z, Zhao W. Role of *Candida albicans* secreted aspartyl proteinases (Saps) in severe early childhood caries. *Int J Mol Sci.* 2014 Jun 13;15(6):10766-9. DOI: 10.3390/ijms150610766
  18. Tamura M, Watanabe K, Mikami J, Yazawa K, Nishimura K. Molecular characterization of new chemical isolates of *Candida albicans* and *Candida dubliniensis* in Japan. Analysis reveals a new genotype of *Candida albicans* with Group I Intron. *J Clin Microbiol.* 2001 Dec;39(12):4309-5. DOI: 10.1128/JCM.39.12.4309-4315.2001
  19. She XD, Wang XJ, Fu MH, Shen YN, Liu WD. Genotype comparisons of strains of *Candida albicans* from patients with cutaneous candidiasis and vaginal candidiasis. *Chin Med J (Engl).* 2008 Aug 5;121(15):1450-5.
  20. McCreight MC, Warnock DW. Enhanced differentiation of isolates of *Candida albicans* using a modified rezistogram method. *Mykosen* 1982 Nov;25(11):589-8. DOI: 10.1111/j.1439-0507.1982.tb01926.x
  21. Nakamura K, Ito-Kuwa S, Nakamura Y, Aoki S, Vidotto V, Sinicco A. Rezistogram typing of the oral *Candida albicans* isolates from normal subjects in three successive trials. *Rev Iberoam Micol.* 1998 Mar;15(1):19-1.
  22. Prince MF, Wilkinson ID, Gentry LO. Plate methods for detection of phospholipase activity in *Candida albicans*. *Sabouraudia.* 1982 Mar;20(1):7-14. DOI: 10.1080/00362178285380031

23. Rasband WS. Image Processing and Analysis in Java (Image J), U.S. National Institutes of Health, Bethesda, Maryland USA, <http://imagej.nih.gov/ij>. Accessed 17 November 2017.
24. Manns JM, Mosser DM, Buckley HR. Production of a haemolytic factor by *Candida albicans*. *Infect Immun.* 1994 Nov;62(11):5154–6.
25. Luo G, Samaranayake LP, You JYY. Candida species exhibit differential in vitro haemolytic activities. *J Clin Microbiol.* 2001 Aug;39(8):2971–4. DOI: 10.1128/JCM.39.8.2971-2974.2001
26. Barros LM, Boriollo MP, Alves AC, Klein MI, Gonçalves RB, Höfling JF. Genetic diversity and exo-enzyme activity of *Candida albicans* and *Candida dubliniensis* isolated from the oral cavity of Brazilian periodontal patients. *Arch Oral Biol.* 2008 Dec;53(12):1172-8. DOI: 10.1016/j.archoralbio.2008.06.003
27. Pierce CG, Uppuluri P, Tristan AR, Wormley FL Jr, Mowat E, Ramage G, et al. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. *Nat Protoc.* 2008;3(9):1494-0. DOI: 10.1038/nprot.2008.141
28. Al-Karaawi ZM, Manfredi M, Waugh ACW, McCullough MJ, Jorge J, Scully C, et al. Characterization of *Candida* spp. isolated from the oral cavities of patients from diverse clinical settings. *Oral Microbiol Immunol.* 2002 Feb;17(1):44-9. DOI: 10.1046/j.0902-0055.2001.00081.x
29. Sugita T, Kurosaka S, Yajitate M, Sato H, Nishikawa A. Extracellular proteinase and phospholipase activity of three genotypic strains of a human pathogenic yeast *Candida albicans*. *Microbiol Immunol.* 2002;46(12):881-3. DOI: 10.1111/j.1348-0421.2002.tb02776.x
30. Willis AM, Coulter WA, Fulton CR, Hayes JR, Bell PM, Lamey PJ. The influence of antifungal drugs on virulence properties of *Candida albicans* in patients with diabetes mellitus. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2001 Mar;91(3):317-1. DOI: 10.1067/moe.2001.112155
31. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. *Clin Microbiol Rev.* 2000 Jan;13(1):122-3. DOI: 10.1128/CMR.13.1.122-143.2000
32. Hannula J, Saarela M, Dogan B, Paatsama J, Kouki-la-Kähkölä P, Pirinen S, et al. Comparison of virulence factors of oral *Candida dubliniensis* and *Candida albicans* isolates in healthy people and patients with chronic candidosis. *Oral Microbiol Immunol.* 2000 Aug;15(4):238-4. DOI: 10.1034/j.1399-302x.2000.150405.x
33. Vidotto V, Koga-Ito CY, Milano R, Fianchino B, Poton J. Correlation between germ tube production, phospholipase activity and serotype distribution in *Candida albicans*. *Rev Iberoam Micol.* 1999 Dec;16(4):208-0.
34. Naglik JR, Challacombe SJ, Hube B. *Candida albicans* secreted aspartyl proteinases in virulence and pathogenesis. *Microbiol Mol Biol Rev.* 2003 Sep;67(3):400-8. DOI: 10.1128/MMBR.67.3.400-428.2003
35. Watanabe T, Takano M, Murakami M, Tanaka H, Matsuhisa A, Nakao N, et al. Characterization of a haemolytic factor from *Candida albicans*. *Microbiology.* 1999 Mar;145(Pt 3):689-4. DOI: 10.1099/13500872-145-3-689
36. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. Our current understanding of fungal biofilms. *Crit Rev Microbiol.* 2009;35(4):340-5. DOI: 10.3109/10408410903241436
37. Kojic EM, Darouiche RO. *Candida* infections of medical devices. *Clin Microbiol Rev.* 2004 Apr;17(2):255-7. DOI: 10.1128/CMR.17.2.255-267.2004
38. Ramage G, Rajendran R, Sherry L, Williams C. Fungal biofilm resistance. *Int J Microbiol.* 2012;2012:528521. DOI: 10.1155/2012/528521
39. Sherry L, Rajendran R., Lappin D.F, Borghi E, Perdoni F, Falleni M, et al. Biofilms formed by *Candida albicans* bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity. *BMC Microbiol.* 2014;14:182-6. DOI: 10.1186/1471-2180-14-182
40. Pierce CG, Srinivasan A, Uppuluri P, Ramasubramanian AK, Lopez-Ribot JL (2013) Antifungal therapy with an emphasis on biofilms. *Curr Opin Pharmacol.* 2013 Oct;13(5):726–0. DOI: 10.1016/j.coph.2013.08.008

